Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Evolva S.A. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is overseen by 1 distinct examiner in 1 distinct art unit. The company's current prosecution is concentrated on this single active matter, reflecting a focused approach to its pharmaceutical patent interests. With only 1 pending office action, the company can dedicate its full attention to the specific technical arguments required for this application.
The busiest examiner for this portfolio is MEAH, MOHAMMAD Y, who is managing 1 busiest examiner pending action. Since this is the only pending action for the company, this examiner's review is the critical factor in the current prosecution cycle. Practitioners should tailor their strategy to this examiner's specific feedback and the standards of the 1 distinct art unit. Success in this 1 pending office action will depend on a clear and persuasive response to the examiner's technical objections.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18351225 | METHOD FOR PRODUCING PHYTOSPHINGOSINE OR PHYTOCERAMIDE | MEAH, MOHAMMAD Y | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18351225 | METHOD FOR PRODUCING PHYTOSPHINGOSINE OR PHYTOCERAMIDE | MEAH, MOHAMMAD Y | 1652 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEvolva S.A. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mohammad Y Meah has the most, with 1 of Evolva S.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
